2018

★ Chiheal Biomed Team's Inception, Embarking on the CRO Mode.

2019

★ Fully Blooming, Entering the Field of Innovative Drugs, Initiating MAH Variety Research and Development CooperationComprehensive Expansion into Innovative Drug Field, Commencement of MAH Variety R&D Collaboration.

2020

★ Rapid Development, Commencement of Formulation Factory Construction.

2021

★ Structural Optimization, Cost Reduction, CRO Scale Doubling, Successive Birth of Innovative Drug PCCs.

2022

★ Initiation of a New Era, High-Efficiency Operations.
★ Introduction of Strategic Cooperative Investments, In-Depth Development, Strengthening R&D Team.
★ Formulation Factory Officially Put into Operation.
★ Commencement of API Factory Construction.

2023

★ Completion of Series A Financing, Reinforcement of R&D Investment;
★ H1 2023: Initiation of New Third Board Listing, Laying the Foundation for Beijing Stock Exchange IPO;
★ Further Optimization of Management Structure, Strengthening Management and Technical Training, Consolidating Robust Operational Foundation;
★ Consolidation of New Teams, Strengthening Technical Platforms; Maturation of CRO, CMO, and CDMO Modes.